Urgent.News

What's breaking now, across thousands of outlets.

More in Tech

Celltrion Secures Global Rights to Kaigene’s KG013, Expanding Autoimmune Drug Pipeline

Celltrion is strengthening its next-generation drug development portfolio by securing global rights to KG013, an investigational antibody therapy for autoimmune diseases developed by U.S.-based…

  • Celltrion secures global rights to KG013 antibody therapy for $580.5 million.
  • KG013 targets APRIL protein to treat IgAN and potentially other immune conditions.
  • Partnership expands Celltrion's autoimmune drug pipeline with two additional Kaigene therapies.

More from Thursday 22 October →